* Acasti Pharma Inc reported a quarterly adjusted loss of 37 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -46 cents. The lone analyst forecast for the quarter was for a loss of 34 cents per share.
* Reported revenue was zero; analysts expected zero.
* Acasti Pharma Inc's reported EPS for the quarter was a loss of 24 cents.
* The company reported a quarterly loss of C$2.62 million.
* Acasti Pharma Inc shares had fallen by 16.4% this quarter and lost 15.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 6.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Acasti Pharma Inc is $6.00 This summary was machine generated from LSEG data August 9 at 02:21 p.m. UTC. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.34 -0.37 Missed
Mar. 31 2024 -0.47 -0.18 Beat
Dec. 31 2023 -0.31 -0.30 Beat
-0.27
Comments